6.9% placebo
While Ozempic (which contains the active ingredient semaglutide) is primarily approved and prescribed in New Zealand for managing type 2 diabetes and reducing associated cardiovascular risks, its effect on appetite and subsequent weight loss has become widely recognised
Weight loss injections, primarily glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound), work through multiple physiological mechanisms to promote weight reduction
If youre sensitive to stimulants or prefer to exercise in the evening, low-stim or stim-free pre-workouts will be a better option, as these contain little to no caffeine
These modifications prolong its half-life, enabling once-weekly dosing and sustained activation of GLP-1 receptors, thereby improving therapeutic adherence and metabolic efficacy[7]
Price cuts for this class of drugs would generally be welcome news, as GLP-1 medications are highly effective at promoting weight loss and improving cardiometabolic health, as well as preventing diabetes and heart, kidney disease and liver disease